

File No.- BMSIC/40030/724-2025/7987

दिनांक:- 15/10/2025

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना
BMSICL की निविदा संख्या- BMSIC/DRUGS/25-10 से संबंधित प्राप्त ई-निविदाओं के तकनीकी
मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/25-10**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 72 (बहत्तर) ई-निविदा प्राप्त हुई। उक्त 72 (बहत्तर) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं **e-proc 2.0 के website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 22/10/2025 के अपराह्न 05:00 बजे तक केवल **e-proc 2.0 के website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के website (www.eproc2.bihar.gov.in) के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त


महाप्रबंधक (अधिप्राप्ति)

ज्ञापांक:- BMSIC/40030/724-2025/7987

दिनांक:- 15/10/2025

प्रतिलिपि :- सहायक प्रबंधक (सिस्टम) एवं प्रबंधक (औषधि) को सूचनार्थ प्रेषित। निदेश है कि सूचना का अनुलग्नक सहित अविलंब BMSICL के **website (www.bmsicl.gov.in)** एवं **e-proc2 (www.eproc2.bihar.gov.in)** पर अपलोड करना सुनिश्चित करें।


महाप्रबंधक (अधिप्राप्ति)



TENDER NO. BMSIC/DRUGS/25-10

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name : - Gnosis Pharmaceuticals Pvt. Ltd. Total Number of Pages Submitted in bid documents: - 01 - 264

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein	Yes	11	Yes	
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	21-25	Yes	
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	14-16	Yes	
4	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted. It's mandatory for the firm to provide a document for the Unique Document Identification Number (UDIN) to verify the documents.	Yes	65-73	Yes	
5	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	33-36	Yes	
6	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	25	Yes	
7	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	30-32	Yes	

Anil Singh

Shree

TENDER NO. BMSIC/DRUGS/25-10

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Gnosis Pharmaceuticals Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 264

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	76	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	4	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	83-111	No	(i) Product specification for NIT sr. no. 7 & 30 are not as per NIT. (ii) Dosage form for NIT sr. no. 71 is not as per NIT.
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	83-111	No	
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945. For drugs with a patent that expired less than 2 years ago from the last date of bid submission: Non-patent holding bidders should submit a valid Market Standing Certificate and valid drug license, issued by the State Drug Licensing Authority in support of the claim. Bidders will be eligible only if one batch of new drug has been successfully manufactured/ imported for commercial use at the time of bidding. Bidders should submit document regarding patent expired less than 2 years ago from the last date of bid submission.	Yes	37-64	No	(i) MSC submitted for Capsule instead of Tablet for NIT sr. no. 71. (ii) Specification for NIT sr. no. 7, 30, 71 & 85 are not as per NIT in submitted MSC.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	

 06/10/25
 14/10/25
 6/10/25

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	112-114	Yes	
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	83-11	No	(i) Product specification for NIT sr. no. 7 & 30 are not as per NIT. (ii) Dosage form for NIT sr. no. 71 is not as per NIT.
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender. Self-attested copies are to be submitted.	Yes	37-64	No	(i) MSC submitted for Capsule instead of Tablet for NIT sr. no. 71. (ii) Specification for NIT sr. no. 7, 30, 71 & 85 are not as per NIT in submitted MSC.
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	26-29	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandis that the GMP certificate should remain valid till the date of submission of tender.	Yes	7	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	8	Yes	

[Signature]
06/10/25

[Signature]

[Signature]
06/10/25

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed /Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II .	Yes	9-10	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	5-6	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	74-75	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	115	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	4	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII	Yes	77-78	Yes	

[Signature]
8/10/25

[Signature]
06/10/25

[Signature]

TENDER NO. BMSIC/DRUGS/25-10

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Gnosis Pharmaceuticals Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 264

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopocial Specification/ Strength		Dosage Form		Pack Size		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	2	Amoxicillin (A) + Clavulanic acid (B)	Amoxycillin & Potassium Clavulanate Oral Suspension IP	200 mg (A) + 28.5 mg (B)/5 ml	Each 5 ml (After reconstitution) contains: 200 mg (A) + 28.5 mg (B)	Oral liquid	Oral Suspension	30ml Bottle (with measuring Cap)	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 38)
2	5	Bromhexin Hydrochloride	Bromhexine HCl Syrup	4 mg/5 ml	4 mg/5 ml	Oral Syrup	Oral Syrup	60ml Bottle (with measuring Cap)	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	11.02.2019	27.04.2027	Generic	Submitted (page no. 40)
3	7	Carbamazepine	Carbamazepine Extended release Tablets IP (Product specification is not as per NIT)	200 mg	Each extended release tablet contains: Carbamazepine IP 200 mg	Tablet	Extended release tablet (Not as per NIT)	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 43) (MSC for extended release)
4	10	Cefixime	Cefixime Oral Suspension IP	100 mg/5 ml	100 mg/5 ml	Oral liquid	Oral Suspension	30ml Bottle (with measuring Cap)	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	13.12.2018	27.04.2027	Generic	Submitted (page no. 45)
5	16	Cholecalciferol	Cholecalciferol Solution USP (page no. 92)	800 IU/ml	800 IU/ml	Drop	Solution	30ml Bottle (with measuring Cap)	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 40)

Shahin
06/10/25

AKP
06/10/25

6	17	Ciprofloxacin	Ciprofloxacin Tablets IP 250 mg (page no. 93)	250 mg	250 mg	Tablet	Tablet	10x10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 40)
7	18	Ciprofloxacin	Ciprofloxacin Tablets IP 500 mg (page no. 94)	500 mg	500 mg	Tablet	Tablet	10x10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 38)
8	19	Clarithromycin	Clarithromycin Tablets IP (page no. 95)	500 mg	500 mg	Tablet	Tablet	10x10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 46)
9	30	Diclofenac Sodium	Diclofenac Gel IP	1% w/v	1% w/w (Not as per NIT)	Gel	Gel	30gm Tube	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	11.02.2019	27.04.2027	Generic	Submitted but specification is not as per NIT. (page no. 58)
10	34	Dried Aluminium Hydroxide + Magnesium Hydroxide + Activated Dimethicone (Antacid)	(Antacid Suspension) Activated Dimethicone Dried Aluminium Hydroxide & Magnesium Hydroxide Suspension (page no. 97)	250mg+ 250mg + 50mg per 5 ml	50 mg + 250 mg + 250 mg per 5 ml	Oral Liquid	Oral Suspension	200 ml	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	23.07.2018	27.04.2027	Generic	Submitted (page no. 42)
11	38	Febuxostat	Febuxostat Tablet	40 mg	40 mg	Tablet	Tablet	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	20.08.2018	27.04.2027	Generic	Submitted (page no. 47)
12	50	Mefenamic acid	Mefenamic Acid Suspension (page no. 99)	100 mg/5 ml	100 mg/5 ml	Oral liquid	Oral Suspension	60 ml Bottle	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 55)

[Signature]
06/10/25

[Signature]
6/10/25

13	51	Mefenamic acid	Mefenamic Acid Tablets (page no. 100)	500 mg	500 mg	Tablet	Tablets	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	20.08.2017	27.04.2027	Generic	Submitted (page no. 49)
14	52	Metformin (Immediate and controlled release)	Metformin HCl Sustained release Tablets IP (page no. 101)	500 mg CR	500 mg SR	Tablet	SR Tablets	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 51)
15	53	Metformin (Immediate and controlled release)	Metformin HCl Prolonged release Tablets IP (page no. 102)	1000 mg CR	1000 mg (Prolonged release Tablets)	Tablet	Prolonged release Tablets	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 58)
16	57	Metronidazole	Metronidazole Benzoate Oral Suspension IP (page no. 103)	200 mg/5 ml	200 mg/5 ml	Oral liquid	Oral Suspension	60 ml bottle	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 40)
17	59	Montelukast	Montelukast Sodium Tablets IP 10 mg (page no. 104)	10 mg	10 mg	Tablet	Tablets	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	11.02.2019	27.04.2027	Generic	Submitted (page no. 60)
18	65	Olanzapine	Olanzapine Tablets IP (page no. 105)	5 mg	5 mg	Tablet	Tablets	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 52)
19	66	Olanzapine	Olanzapine Tablets IP (page no. 106)	10 mg	10 mg	Tablet	Tablets	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 66)

[Signature]
06/10/25

[Signature]
6/10/25 NPS

20	68	Paracetamol	Paracetamol Paediatric Oral Suspension IP (page no. 107)	100 mg/ml	100 mg/ml	Paediatric Oral Suspension (Drop)	Paediatric Oral Suspension	15ml Bottle	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	11.02.2019	27.04.2027	Generic	Submitted (page no. 62)
21	69	Paracetamol	Paracetamol Oral Suspension IP (page no. 108)	250 mg/5ml	250 mg/5ml	Oral Liquid	Oral Suspension	60 ml	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	28.09.2017	27.04.2027	Generic	Submitted (page no. 62)
22	71	Pregabalin	Pregabalin Capsule IP 75 mg (Product specification is not as per NIT) (page no. 109)	75 mg	75 mg	Tablet	Capsule (Not as per NIT)	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	11.02.2019	27.04.2027	Generic	Submitted for Capsule (page no. 53)
23	81	Tranexamic acid	Tranexamic Acid Tablets IP	500 mg	500 mg	Tablet	Tablet	10 x 10	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	13.12.2018	27.04.2027	Generic	Submitted (page no. 47)
24	85	Zinc sulphate	Zinc sulphate Syrup	20mg/5ml	20mg/5ml	Oral Solution	Oral Syrup	100 ml Bottle	Pack size as per schedule P1 of Drug & Cosmetic Act 1945.	11.02.2019	27.04.2027	Generic	Submitted but specification not as per NIT (page no. 64).

Handwritten signature
06/10/25

Handwritten signature
6/10/25
NND


TENDER NO. BMSIC/DRUGS/25-10

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Gnosis Pharmaceuticals Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 264



Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	2	Amoxicillin (A) + Clavulanic acid (B)	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
2	5	Bromhexin Hydrochloride	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
3	7	Carbamazepine	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
4	10	Cefixime	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
5	16	Cholecalciferol	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
6	17	Ciprofloxacin	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
7	18	Ciprofloxacin	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027


06/10/25


06/10/25

8	19	Clarithromycin	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
9	30	Diclofenac Sodium	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
10	34	Dried Aluminium Hydroxide + Magnesium Hydroxide + Activated Dimethicone (Antacid)	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
11	38	Febuxostat	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
12	50	Mefenamic acid	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
13	51	Mefenamic acid	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
14	52	Metformin (Immediate and controlled release)	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
15	53	Metformin (Immediate and controlled release)	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
16	57	Metronidazole	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027

 06/10/25
 06/10/25

17	59	Montelukast	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
18	65	Olanzapine	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
19	66	Olanzapine	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
20	68	Paracetamol	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
21	69	Paracetamol	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
22	71	Pregabalin	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
23	81	Tranexamic acid	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027
24	85	Zinc sulphate	25 & 28	MNB/07/541 & MB/07/542	NA	NA	28.04.2007	27.04.2027	20.12.2024	27.04.2027

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/724-2025/5183 dt 13.08.2025 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due diligence and care. In spite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepancies are observed for rectification.

[Signature]
06/10/25

[Signature]
6/10/25